Reported 2 days ago
ImmunityBio, Inc. (IBRX) soared 8.1% to $2.93 per share, marking its fifth consecutive day of gains, following the FDA's approval to expand access to its Anktiva treatment for patients suffering from solid tumors. Company founder Patrick Soon-Shiong highlighted the significance of addressing lymphopenia, a condition linked to higher cancer mortality rates. Following this announcement, HC Wainwright issued a 'buy' recommendation with a price target of $8 for the stock.
Source: YAHOO